Screening for cervical cancer is critically important to women’s health. In the United States, it is estimated that in 2026, approximately 13,490 new cases of invasive cervical cancer will be ...
Hologic, Inc. announced today that Health Canada has granted medical device licenses for Hologic's APTIMA HPV and APTIMA HPV 16 18/45 genotype assays. Both assays are in vitro nucleic acid ...
Hologic has received the US Food and Drug Administration (FDA) approval for its Aptima HPV assay for use in clinician-collected primary screening, further expanding its cervical health portfolio. The ...
“Hologic has been at the forefront of cervical cancer screening for decades, and the additional indication of the Aptima HPV Assay reflects our ongoing commitment to advancing women’s health through ...
MARLBOROUGH, Mass., February 04, 2026--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima ® HPV Assay received FDA approval for clinician-collected HPV primary screening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results